Top Gainers Pre-Market Notes -- Research on bebe stores, BioTelemetry, Axcelis Technologies, and Nanosphere
PR Newswire - Mon May 12, 10:30AM CDT
On Friday, May 9, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average advanced 0.20% to finish the day at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. During the session gains in the Consumer Discretionary, Health Care, and Consumer Staples sectors positively impacted the broader market, while some retraction came in from Utilities, Energy, and Financials sectors. A number of stocks saw large movements, including bebe stores inc. (NASDAQ: BEBE), BioTelemetry Inc. (NASDAQ: BEAT), Axcelis Technologies Inc. (NASDAQ: ACLS) and Nanosphere Inc. (NASDAQ: NSPH). Free technical research on BEBE, BEAT, ACLS and NSPH can be downloaded upon signing up at:
Axcelis Technologies (ACLS) in Focus: Stock Tumbles 9.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 7:31AM CDT
Axcelis Technologies (ACLS) fell over 9% in the last trading session amid huge volumes, continuing its recent downtrend, as the stock is down over 21% in the past one-month time frame.
Axcelis To Present At The 15th Annual B. Riley & Co. Investor Conference
PR Newswire - Thu May 08, 7:00AM CDT
Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the 15th Annual B. Riley & Co. Investor Conference. The conference is scheduled for May 19-21, 2014 at the Loews Santa Monica Hotel, in Santa Monica, CA.
Investors look to Lighten Up on Shares of Axcelis Technologies, Shares Down 10.2% (ACLS)
Comtex SmarTrend(R) - Wed May 07, 10:13AM CDT
Axcelis Technologies (NASDAQ:ACLS) is one of today's worst performing low-priced stocks, down 10.2% to $1.59 on 1.0x average daily volume. Axcelis Technologies has traded 608,000 shares thus far today, vs. average volume of 600,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's 0.1%) and underperformed the S&P 500 (-10.2% to the S&P's -0.0%) during today's trading.
Axcelis Announces Financial Results For First Quarter 2014
PR Newswire - Tue May 06, 3:01PM CDT
Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced financial results for the first quarter ended March 31, 2014. Highlights for the quarter were:
Time to Buy Axcelis (ACLS) After Recent Moving Average Crossover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:45AM CDT
Time to Buy Axcelis (ACLS) After Recent Moving Average Crossover?
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Multi-System Follow-On Order Received For Axcelis Optima HDx High Current Implanter
PR Newswire - Wed Apr 23, 7:00AM CDT
Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced it received a follow-on order for the Optima HDx high current implanter from one of the world's leading chipmakers located in the Asia Pacific region. As process tool of record, the Optima HDx will be used in high volume manufacturing of next generation memory products. The systems shipped in the first quarter.
Axcelis Announces Order For 'Purion M' Medium Current Implanter From Second Leading Chip Manufacturer
PR Newswire - Tue Apr 15, 7:00AM CDT
Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today that it has received an order for the Company's next generation Purion M(TM) medium current implanter from a second leading chipmaker in Asia. The system was ordered after a very successful evaluation process where the product exceeded goals in numerous performance categories. Utilizing Axcelis' industry leading Contamination Shield(TM) and Vector(TM) technology the Purion M demonstrated unmatched levels of purity and precision while simultaneously achieving a new benchmark in productivity for the customer's most advanced technologies.
Axcelis Announces Timing And Availability Of First Quarter 2014 Results And Conference Call
PR Newswire - Tue Apr 08, 7:00AM CDT
Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced it will hold its earnings call to discuss results for the first quarter 2014 results on Tuesday, May 6, 2014 at 5:00 pm ET. The call will be available to interested listeners via an audio webcast that can be accessed through the Investors page of Axcelis' website at www.axcelis.com, or by dialing 1.888.679.8035 (1. 617.213.4848 outside North America). Participants calling into the conference call will be requested to provide the company name, Axcelis Technologies, and pass code: 36177541. Webcast replays will be available for 90 days following the call.
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
Stock to Avoid: Axcelis Technologies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 2:40PM CDT
Zacks Investment Research downgraded Axcelis Technologies Inc. to a Zacks Rank #5 (Strong Sell) on Mar 26, 2014.
Axcelis Wins 2014 Leader Award For Excellence In Commuter Options For Fourth Consecutive Year
PR Newswire - Wed Mar 26, 7:00AM CDT
Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, is being recognized with a Leader Award, for the fourth consecutive year, for Excellence in Commuter Options (ECO). The annual Mass ECO Awards honor Massachusetts employers and their efforts to reduce congestion and greenhouse gas emissions by encouraging employees to utilize green transportation options like walking, cycling, carpools and mass transit. The awards ceremony is scheduled for today at Fenway Park in Boston, MA.
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
Hot Stock: Axcelis Technologies, Shares Gain 6.6% (ACLS)
Comtex SmarTrend(R) - Tue Mar 11, 10:11AM CDT
Axcelis Technologies (NASDAQ:ACLS) is one of today's best performing low-priced stocks, up 6.6% to $2.41 on 1.4x average daily volume. Axcelis Technologies has traded 1.2 million shares thus far today, vs. average volume of 850,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.2%) and outperformed the S&P 500 (6.6% to the S&P's 0.2%) during today's trading.
Axcelis Ships Multiple System Order For 'Purion XE' High Energy Implanters
PR Newswire - Tue Mar 11, 7:00AM CDT
Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced that it has received a multiple system order for the Company's new Purion XE(TM) single wafer, high energy implanter. The Purion XE, which is the process tool of record for this customer's high energy requirements, will be installed as part of a capacity expansion at a fab in the Asia Pacific Region, and will be used in high volume production of advanced NAND devices. The systems ship in Q1.
Axcelis To Present At The Piper Jaffray Technology, Media And Telecommunications Conference
PR Newswire - Wed Feb 26, 7:00AM CST
Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the Piper Jaffray Technology, Media and Telecommunications Conference. The conference is scheduled for March 11-12th at Le Parker Meridien in New York.
Why Axcelis Technologies (ACLS) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 8:00AM CST
It may be a good decision to sell Axcelis Technologies as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.